Risk of deteriorating profitability from revisions to drug-price standards and dispensing fees
First written in FY2022. 5 of 14 entries say "Restated". Latest entry: 2026-08-12.
Hyuga Primary Care moved to the "Worse" side of this theme in 2026, the same year as the typical company in this theme.
1 other company's latest entry also says "Mitigated".
- FY2026WorsenedAnnual report
「Meanwhile, the April 2026 revision of dispensing fees (effective June 2026) is expected to expand services for home-care patients, particularly those provided at private residences, while revisions to dispensing management fees and other items are expected to reduce technical fees. Together with measures to raise employee wages, this is increasing pressure on profit margins.」
The April 2026 revision of dispensing fees is described as having both the effect of expanding home-care services and reducing technical fees, with rising pressure on profit margins including the response to wage increases. - FY2026-H1RestatedAnnual report
「In the healthcare and nursing care industries in which our group operates, dispensing fees and nursing care fees were revised in June 2024 (the revision of drug prices and related items was in April 2025), and the baby-boomer generation is becoming part of the late-stage elderly population, marking the beginning of a full-scale era of home healthcare and nursing care.」
The industry environment following the revisions to dispensing fees and nursing care fees, and the April 2025 revision of drug prices and related items, continues to be disclosed. - FY2025RestatedAnnual report
「If annual revisions lower the official drug price schedule without a comparable reduction in drug purchase prices, or if dispensing fees are reduced in the biennial revision of dispensing fees (the latest revision was in April 2024), this may affect the performance and other aspects of our group.」
The risk of fluctuations in drug purchase prices and dispensing fee points resulting from revisions to the official drug price schedule and dispensing fees continues to be disclosed, with the date of the latest revision updated. - FY2025-H1MaterialisedAnnual report
「During the six-month consolidated period, the negative revision to drug prices effective April 2024 had an impact, while the increase in dispensing fees for home-care patients, including the newly established comprehensive home-care pharmacy system surcharge, took effect in June. As a result, the Company was negatively affected, like general outpatient pharmacies. From July onward, profit increased steadily, with segment profit rising to ¥183 million in the period from July to September, approximately double the ¥94 million recorded in the period from April to June.」
The impact of the negative drug price revision in April 2024 materialized, and segment profit in the home-visit pharmacy business was ¥94 million from April to June. By contrast, it increased to ¥183 million from July to September, approximately double the earlier figure. - FY2024-Q3RestatedAnnual report
「The revision of dispensing fees has led to lower drug prices and stronger fee points in the home-care field, creating an environment in which pharmacies are increasingly required to enter home healthcare in earnest.」
The Company continues to describe an environment in which declining drug prices and stronger fee points in the home-care field coexist, and entry into home healthcare is increasingly required. - FY2024-Q2RestatedAnnual report
「The revision of dispensing fees has led to lower drug prices and stronger fee points in the home-care field, creating an environment in which pharmacies are increasingly required to enter home healthcare in earnest.」
The Company continues to describe an environment in which the decline in drug prices and strengthening of fee points in the home-care field coexist, and entry into home healthcare is increasingly required. - FY2024-Q1RestatedAnnual report
「The revision of dispensing fees has resulted in lower drug prices, while fee points in the home-care field, including regional system surcharges, have increased. As conventional outpatient pharmacies face increasingly difficult operating conditions, the revision is a tailwind for companies such as the Company that have strengths in serving home-care patients.」
The Company continues to describe the simultaneous decline in drug prices and strengthening of fee points in the home-care field following the dispensing fee revision, a situation that is a tailwind for the Company because of its strength in serving home-care patients. - FY2023-Q3The effects of regulatory revisions continue, with declining drug prices and strengthening of the home-care fieldAnnual report
「The revision of dispensing fees has led to lower drug prices and stronger fee points in the home-care field, creating an environment in which pharmacies are increasingly required to enter home healthcare in earnest.」
The Company continues to describe the simultaneous decline in drug prices and strengthening of fee points in the home-care field following the dispensing fee revision. - FY2023-Q1The effects of regulatory revisions have become apparent, with mixed impactsAnnual report
「The revision of dispensing fees has resulted in lower drug prices, while fee points in the home-care field, including regional system surcharges, have increased. As conventional outpatient pharmacies face increasingly difficult operating conditions, the revision is a tailwind for companies such as the Company that have strengths in serving home-care patients.」
The Company describes simultaneous declines in drug prices and increases in fee points in the home-care field following the dispensing fee revision. Although the decline in drug prices has had an impact, the Company explains that the revision is a tailwind for its home-care operations. - FY2022First statedAnnual report
「Alternatively, if the dispensing fee revision that occurs every 2 years, most recently in April 2022, results in lower dispensing fee points, the Company's performance could be affected.」
The Company describes the performance risk associated with annual revisions to official drug prices and biennial revisions to dispensing fees, through lower drug procurement prices and dispensing fee points.